NRC FORM 591M PART 1 U.S. NUCLEAR REGULATORY COMMISSION								
(07-2012) SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATION INSPECTED: 2. NRC/REGIONAL OFFICE								
IBA Molecular North America, Inc. 21000 Atlantic Boulevard Suite No. 730			Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210					
Dulles, Virginia 20166			Lisle, IL 60532-4352	· ·				
REPORT NUMBER(S) 12-01								
3. DOCKET NUMBER(S	5)	4. LICENSE NUMB	ER(S)	5. DATE(S) OF INSPECTIC	N .			
030-38113		45-25221-05		November 15, 201	2			
LICENSEE: The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows: Image: Procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows: Image: Procedures and the inspection findings, no violations were identified. 2. Previous violation(s) closed. 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied. Image: Provide violation(s) were discussed involving the following requirement(s):								
 During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions) 								
Statement of Corrective Actions I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.								
TITLE	PRINTED NAME		SIGNATURE		DATE			
LICENSEE'S REPRESENTATIVE			-					
NRC INSPECTOR	Robert P. Hays		ZAR TH	un l	11/15/1-			
BRANCH CHIEF	Tamara E. Bloomer		FBloom_	00	11/1/12			

NRC FORM 591M PART 3			UE	NUCLEAR REGULATORY COMMISSION				
(07-2012) 10 CFR 2.201		Docket File Info		NUCLEAR REGULATORY COMMISSION				
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATION INSP	ECTED:		2. NRC/REGIONAL OFFICE					
IBA Molecular North	America Inc							
IBA Molecular North America, Inc. 21000 Atlantic Boulevard			Region III					
Suite No. 730			U. S. Nuclear Regulatory Commission					
Dulles, Virginia 20166	5		2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352					
REPORT NUMBER(S) 12	-01	,						
3. DOCKET NUMBER(S)		4. LICENSE NUMBER	5)	5. DATE(S) OF INSPECTION				
030-38113		45-25221-05		November 15, 2012				
6. INSPECTION PROCEDURES USED		7. INSPECTION FOCU	S AREAS					
87125		03.01-03.07	03.01-03.07					
SUPPLEMENTAL INSPECTION INFORMATION								
1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTAC	T	4. TELEPHONE NUMBER				
3210	2	Michael Roberts	, RSO	(816) 801-8544				
Main Office Ins	pection	Next Inspectior	Date: 11/15/	/2014				
Field Office Ins	pection 8614 N	W 107th Terrace, Kansa	is City, Missouri					
Temporary Job	Site Inspection							
	•							
		PROGRAM S						
The licensee is authorized for production of activated radionuclides used for PET imaging and medical diagnosis of disease and transfered to a nuclear pharmacy for preparation and distribution to licensees authorized for PET studies. Although the licensee is authorized for production of various radionuclides, only two compounds of flourine-18 are produced and distributed. Production runs each day except Sunday and start times can vary depending on the amount of F-18 that is required to fill orders for the nuclear pharmacy. The staff working under the license includes a cyclotron engineer and other staff as needed from the nuclear pharmacy.								
Performance Observations								
During the inspection, the licensee's RSO and staff demonstrated/discussed: (1) survey meter calibrations; (2) ambient and contamination surveys and surveys; (3) hot cell operations and procedures; (4) sealed source inventory; (5) routine security of licensed material; (6) emergency procedures; (7) radiation safety program audits; (8) dosimetry; (9) staff training; (10) effluent monitoring; (11) waste storage and removal; (12) material accountability; (13) contamination events; (14) target events; (15) dosimetry; [CY 2011: 1938mr-DDE; 4900mr-SDE], [2012 to October 7: 5500mr-SDE]								
The inspector performed independent radiation measurements which indicated no dose concerns and consistent with licensee survey records and postings.								
· .								